Welcome to our dedicated page for Cullinan Therapeutics SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cullinan Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cullinan Therapeutics's regulatory disclosures and financial reporting.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an exercise-and-sell transaction in company stock. She sold 8,000 shares of common stock in an open-market sale at a weighted average price of $17.82 per share, executed under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2025. On the same date, she exercised stock options for 4,000 shares of common stock at an exercise price of $4.30 per share. After these transactions, she directly owned 162,844 shares of Cullinan Therapeutics common stock and held 112,987 stock options exercisable at $4.30 per share, which expire on October 28, 2030.
Company CGEM: proposed resale notice under Section 144. The filing lists proposed sales of 8,000 shares of Common Stock tied to insider-related sources. The listing shows 4,000 shares from exercise of stock options dated 07/06/2026 and 4,000 shares from Restricted Stock Units dated 02/22/2024. The excerpt also records prior 10b5-1 sales of 8,000 shares on 05/05/2026 for $116,976.02. The filing names a broker and provides an address for the selling party.
Cullinan Therapeutics Chief Legal Officer Jacquelyn L. Sumer acquired 2,470 shares of common stock at $8.60 per share through the company’s 2021 Employee Stock Purchase Plan. The shares relate to the purchase period from January 1, 2026 through June 30, 2026 and were bought at 85% of the January 2, 2026 closing price. Following this routine ESPP transaction, she directly holds 130,559 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics Chief Financial Officer Mary Kay Fenton reported an acquisition of company stock through the 2021 Employee Stock Purchase Plan. She obtained 1,541 shares of common stock for the purchase period from January 1, 2026 through June 30, 2026.
The shares were bought at $8.60 per share, based on 85% of the closing price on January 2, 2026, as provided under the ESPP. Following this routine, compensation-related transaction, she directly holds 127,921 shares of Cullinan Therapeutics common stock.
Cullinan Therapeutics director Anthony Rosenberg received a grant of stock options covering 25,319 shares of Common Stock. The options have an exercise price of $13.55 per share and will vest in full on the earlier of June 16, 2027 or the company’s next annual meeting, contingent on his continued board service. Following this compensation grant, he holds options for 25,319 underlying shares directly, with no open-market buying or selling reported in this filing.
Cullinan Therapeutics director David D. Meek received a new stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and represents a right to buy the company’s common stock directly.
According to the grant terms, the 25,319-share option will vest in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting, provided Meek continues to serve as a director through that vesting date. Following this grant, he holds stock options for 25,319 shares.
Cullinan Therapeutics director Stephen W. Webster received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was awarded as compensation, not an open-market purchase or sale. It vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, contingent on his continued board service. Following this grant, Webster holds options for 25,319 underlying shares.
Cullinan Therapeutics director Andrew R. Allen received a grant of stock options covering 21,781 shares of common stock at an exercise price of $13.55 per share. These options vest in full on the earlier of June 16, 2027 or the company’s next annual meeting, subject to his continued board service.
Cullinan Therapeutics director Mary Thistle received a stock option grant covering 25,319 shares of common stock. The option has an exercise price of $13.55 per share and was granted at no cost to her.
The award vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director on that date. Following this grant, she holds options for 25,319 underlying shares.
Cullinan Therapeutics director Mittie Doyle received a new stock option grant. The award covers 21,781 shares of Common Stock at an exercise price of $13.55 per share. According to the terms, the option vests in full on the earlier of June 16, 2027 or the company’s next annual meeting, as long as she continues serving as a director.